0
With tropical heat, remote island communities, a dearth of ultra-cold freezers and a limited quantity available, many Asian countries and developing nations aren’t betting on Pfizer’s experimental vaccine solving their Covid-19 crisis any time soon.
The world cheered on Monday when Pfizer Inc announced its shot, jointly developed with BioNTech SE, was more than 90 per cent effective based on initial trial results.
Yet health experts cautioned that the vaccine, should it be approved, was no silver bullet — not least because the genetic material it’s made from needs to be stored at temperatures of minus 70 degrees Celsius or below.
Read more here.
